Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 537 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Dad Sings “Ave Maria” For His Daughter At Disney World April 8, 2019 Mental Health Awareness for Health Care Providers May 21, 2021 From athlete to wig-maker: how cancer changed Maria’s destiny December 16, 2022 Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma
